Nancy L Bartlett

Nancy L Bartlett

UNVERIFIED PROFILE

Are you Nancy L Bartlett?   Register this Author

Register author
Nancy L Bartlett

Nancy L Bartlett

Publications by authors named "Nancy L Bartlett"

Are you Nancy L Bartlett?   Register this Author

100Publications

3733Reads

38Profile Views

Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience.

Clin Lymphoma Myeloma Leuk 2019 Dec 30;19(12):806-811. Epub 2019 Sep 30.

Division of Medical Oncology, Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.09.604DOI Listing
December 2019

Reply to T.M. Weis et al.

J Clin Oncol 2019 Nov 18;37(31):2953. Epub 2019 Sep 18.

Nancy L. Bartlett, MD, Washington University School of Medicine, St Louis, MO; Wyndham H. Wilson, MD, PhD, National Institutes of Health, Bethesda, MD; and John P. Leonard, MD, Weill Medical College of Cornell University, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01617DOI Listing
November 2019

Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome.

Clin Lymphoma Myeloma Leuk 2019 Sep 29;19(9):e532-e535. Epub 2019 May 29.

Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.05.015DOI Listing
September 2019

To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma.

J Oncol Pharm Pract 2019 Jun 20;25(4):1027-1030. Epub 2019 Feb 20.

6 Washington University of Medicine, Siteman Cancer Center, St. Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155219831435DOI Listing
June 2019

Chemotherapy-Induced First Bite Syndrome: A Case Report in a Patient With Hodgkin Lymphoma.

Ear Nose Throat J 2019 Jun 8;98(5):E30-E31. Epub 2019 Apr 8.

1 Department of Otolaryngology-Head & Neck Surgery, Washington University School of Medicine in St Louis, St Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0145561319840534DOI Listing
June 2019

Parameters for Validating a Hospital Pneumatic Tube System.

Clin Chem 2019 May 26;65(5):694-702. Epub 2019 Feb 26.

Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University, St. Louis, MO;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2018.301408DOI Listing
May 2019

Progressive multifocal leukoencephalopathy treated with nivolumab.

J Neurovirol 2019 Apr 12;25(2):284-287. Epub 2019 Mar 12.

Department of Neurology, Washington University in St. Louis, Box 8111, 660 South Euclid Avenue, Saint Louis, MO, 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13365-019-00738-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506384PMC
April 2019

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

N Engl J Med 2018 12 1;379(26):2517-2528. Epub 2018 Dec 1.

From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); Stanford University School of Medicine, Stanford (S.C.), and the City of Hope Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1812836DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325637PMC
December 2018

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

N Engl J Med 2018 Nov;379(18):1711-1721

From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1807315DOI Listing
November 2018

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

N Engl J Med 2018 09;379(10):934-947

From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d'Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and Département d'Hématologie, Université de Rouen, Rouen (H.T.), Institut d'Hématologie de Basse Normandie, Caen (C.F.), CHU Le Bocage Service d'Hématologie Clinique, Dijon (R.-O.C.), Hôpital Henri Mondor Unité Hémopathies Lymphoïdes, Créteil (C.H.), Centre Hospitalier Départemental Vendée Service d'Onco-Hématologie, La Roche sur Yon (H.M.), Institut Universitaire du Cancer de Toulouse Oncopole Service d'Hématologie, Toulouse (L.Y.), CHU Bordeaux, Service d'Hématologie, Bordeaux (K.B.), Hôpital Saint Louis Service d'Onco-Hématologie, Paris (P.B.), Gustave Roussy Cancer, Villejuif (V.R.), Centre Hospitalier Annecy Genevois Service, Annecy (N.D.), CHU de Nantes-Hôtel Dieu Service d'Hématologie Clinique, Centre de Recherche en Cancerologie et Immunologie, INSERM, Centre National de la Recherche Scientifique, Université de Nantes, Nantes (S.L.G.), Centre Hospitalier Métropole Savoie Service Hématologie, Chambery (G.M.P.), Department of Hematology, CHU Montpellier, University of Montpellier, Montpellier (G.C.), and Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, University of Lyon, Pierre-Benite (G.A.S.) - all in France; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (N.H.F.); the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (M.L.P.); the Department of Medicine, Division of Medical Oncology, University of Washington, Seattle (E.N.L.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.W.F.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (N.L.B.); the Department of Hematology, Hospital Universitario de Salamanca and Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Salamanca (A.M.G.-S.), and the Department of Hematology, Hospital Clinic de Barcelona, Barcelona (A.L.-G.) - both in Spain; CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec (J.-F.L.), and British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia, Vancouver (L.H.S.) - both in Canada; the Department of Hematology and Oncology, Tokai University Hospital, Kanagawa, Japan (K.A.); Instituto Português de Oncologia Lisboa Francisco Gentil Departamento de Hematologia, Lisbon (M.G.S.); the Department of Hematology, CHU Université Catholique de Louvain Namur, Yvoir (M.A.), and the Department of Hematology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp (P.Z.) - both in Belgium; the Department of Hematology, National Cancer Center Hospital, Tokyo, Japan (K.T.); and Celgene, Summit, NJ (D.L., J.W.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805104
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805104DOI Listing
September 2018

CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.

Expert Opin Investig Drugs 2018 07 5;27(7):601-611. Epub 2018 Jul 5.

a Washington University School of Medicine , St. Louis , MO.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13543784.2018.1
Publisher Site
http://dx.doi.org/10.1080/13543784.2018.1492549DOI Listing
July 2018

Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.

Blood 2018 04 2;131(15):1698-1703. Epub 2018 Mar 2.

Division of Medical Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-09-772681DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536701PMC
April 2018

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

N Engl J Med 2018 04;378(15):1396-1407

From the Lymphoid Malignancies Branch (R.S., D.W.H., J.D.P., J.Q.W., S.R., M.K., R.M.Y., A.L.S., D.J.H., W. Xiao, X.Y., Y.Y., H.Z., W. Xu, W.H.W., L.M.S.), the Biometric Research Program, Division of Cancer Diagnosis and Treatment (G.W.W.), and the Laboratory of Pathology, Center for Cancer Research (E.S.J., S.P.), National Cancer Institute, and the Office of Intramural Research, Center for Information Technology (C.A.J., X.L., B.Z., W.D.), National Institutes of Health, Bethesda, and the Cancer Research Technology Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (B.T., J.S., Y.Z., D.R.S.) - all in Maryland; the Department of Pathology, City of Hope National Medical Center, Duarte, CA (W.C.C.); the BC Cancer Agency, Vancouver, BC (R.D.G., J.M.C.), and the University Health Network, Laboratory Medicine Program, Toronto General Hospital and University of Toronto, Toronto (J.D.) - both in Canada; the Hospital Clinic of Barcelona, University of Barcelona, Institute for Biomedical Research August Pi I Sunyer, Barcelona (E.C., A.L.-G.); the Institute of Pathology, University of Würzburg, and Comprehensive Cancer Center Mainfranken, Würzburg (A.R.), and the Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart (G.O.) - all in Germany; the Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ (L.M.R.); the National Cancer Centre of Singapore, Singapore (K.T.K.W.); Memorial Sloan Kettering Cancer Center (A.D.Z.) and Weill Cornell Medicine (J.P.L.) - both in New York; the Department of Medicine, Washington University School of Medicine, St. Louis (N.L.B.); and the Alliance for Clinical Trials in Oncology, Chicago (A.D.Z., J.P.L., N.L.B.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1801445
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1801445DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010183PMC
April 2018

Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study.

Leuk Lymphoma 2018 02 9;59(2):357-362. Epub 2017 Jun 9.

b Siteman Comprehensive Cancer Center, Washington University , St. Louis , MO , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1330954DOI Listing
February 2018

SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma.

Clin Lymphoma Myeloma Leuk 2018 02 4;18(2):81-90. Epub 2018 Jan 4.

Washington University School of Medicine, St. Louis, MO. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.01.001DOI Listing
February 2018

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

N Engl J Med 2018 01 10;378(4):331-344. Epub 2017 Dec 10.

From the University of British Columbia and the Department of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, Canada (J.M.C., K.J.S.); the Department of Hematology, Jagiellonian University, Krakow (W.J.), the Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw (E.L.-M.), the Department of Hematology and Transfusion Medicine, Center of Postgraduate Medical Education, Warsaw (E.L.-M.), the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.), and the Department of Lymphoid Malignancy, the Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warsaw (J.W.) - all in Poland; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (D.J.S., A.Y.); the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the Division of Hematology and Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea (W.S.K.); Research Innovation and Statistics, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); Petrov Research Institute of Oncology, St. Petersburg, Russia (S.A.); the Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen (Á.I.), and the Department of Hematology, National Institute of Oncology, Budapest (A.R.) - both in Hungary; the Department of Advanced Biomedical Science, Federico II University Hospital, Naples (M.P.), and the Institute of Hematology Seràgnoli, University of Bologna, Bologna (P.L.Z.) - both in Italy; the Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston (Y.O.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ (T.F.); the Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis (N.L.B.); the Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA (R.C.); the Department of Hematology-Oncology, Barbara Ann Karmanos Cancer Center, Detroit (R.R.); Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Sutton (D.C.), and the Department of Medical Oncology, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester (J.R.) - both in the United Kingdom; the Department of Clinical Development, Seattle Genetics, Bothell, WA (N.C.J., E.S.); and Oncology Clinical Research (J.S., H.A.J., D.H.) and Global Biostatistics (R.L.), Millennium Pharmaceuticals, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1708984DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819601PMC
January 2018

Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.

Biol Blood Marrow Transplant 2017 Dec 26;23(12):2199-2204. Epub 2017 Aug 26.

Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.08.022DOI Listing
December 2017

Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.

Authors:
Nancy L Bartlett

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):317-323

Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2017.1.317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142541PMC
December 2017

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

N Engl J Med 2017 12 10;377(26):2531-2544. Epub 2017 Dec 10.

From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N., J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A. Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University, Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.), University of California at Los Angeles, Los Angeles (J.M.T.), University of California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B., J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California; Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center, Bronx (I.B.), and the University of Rochester School of Medicine, Rochester (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.), Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H., M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.); University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (I.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1707447DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882485PMC
December 2017

Magnetic resonance image guided radiation therapy for primary splenic diffuse large B-cell lymphoma: A teaching case.

Pract Radiat Oncol 2017 Jan - Feb;7(1):e23-e26. Epub 2016 Jun 15.

Department of Radiation Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prro.2016.06.004DOI Listing
April 2017

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

J Natl Cancer Inst 2017 04 31;109(4). Epub 2016 Dec 31.

Affiliations of authors: NYU Perlmutter Cancer Center, New York, NY (CSD); BC Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada (JMC); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY (JWF); Department of Medicine, Weil Cornell University, New York, NY (JPL); Oncology Division, Department of Medicine, Washington University, St. Louis, MO (BSK, NLB); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), Tufts Cancer Center and Division of Hematology/Oncology, Tufts University School of Medicine, Boston, MA (AME); Stanford Cancer Institute, Stanford University Medical School, Stanford, CA (RTH); Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Columbia University Medical Center, New York, NY (KMK); Department of Medicine, University of Arizona Cancer Center, Tucson, AZ (DOP); Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY (AY); Department of Radiology, Mount Sinai Hospital, New York, NY (LK).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059238PMC
April 2017

Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome.

Appl Immunohistochem Mol Morphol 2016 07;24(6):383-91

*Department of Pathology and Immunonology, Washington University Medical Center Divisions of †Biostatistics ‡Oncology, Washington University School of Medicine, Saint Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000200DOI Listing
July 2016

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

J Clin Oncol 2016 06 11;34(17):2020-7. Epub 2016 Apr 11.

Oliver W. Press, Fred Hutchinson Cancer Research Center, and the University of Washington; Hongli Li and Michael LeBlanc, Fred Hutchinson Cancer Research Center, Seattle, WA; Heiko Schöder, David J. Straus, Craig H. Moskowitz, and Ariela Noy, Memorial Sloan Kettering Cancer Center; John P. Leonard, Weill Cornell Medical College and New York Presbyterian Hospital, New York City; Paul M. Barr and Jonathan W. Friedberg, University of Rochester Medical Center, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett and Brad S. Kahl, Washington University School of Medicine, St. Louis, MO; Andrew M. Evens, Tufts Medical Center; Ann S. LaCasce, Dana-Farber Cancer Institute, Boston, MA; Erik S. Mittra, Stanford University Medical Center, Stanford, CA; John W. Sweetenham, Huntsman Cancer Hospital, Salt Lake City, UT; Michelle A. Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Michael V. Knopp, The Ohio State University, Columbus; Eric D. Hsi, Cleveland Clinic Foundation; James R. Cook, Cleveland Clinic, Cleveland, OH; Mary Jo Lechowicz, Winship Cancer Institute of Emory University, Atlanta, GA; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC; Bruce D. Cheson, Georgetown University Hospital, Washington DC; and Richard I. Fisher, Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.1119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966513PMC
June 2016

A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.

Expert Opin Drug Saf 2016 Jun 5;15(6):875-82. Epub 2016 May 5.

a Division of Oncology , Washington University School of Medicine , St. Louis , MO , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2016.1179277DOI Listing
June 2016

Fine-Tuning the Treatment of Hodgkin's Lymphoma.

Authors:
Nancy L Bartlett

N Engl J Med 2016 Jun;374(25):2490-2

From the Division of Oncology, Department of Medicine, and Siteman Cancer Center, Washington University School of Medicine, St. Louis.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1604026DOI Listing
June 2016

Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.

Leuk Lymphoma 2016 May 20;57(5):1191-3. Epub 2015 Oct 20.

a Division of Oncology , Washington University School of Medicine , St. Louis , MO , USA ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1096356DOI Listing
May 2016

Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.

J Clin Oncol 2016 05 28;34(14):1620-5. Epub 2016 Mar 28.

Jon Glass and Maria Werner-Wasik, Thomas Jefferson University; Minhee Won, NRG Oncology Statistics and Data Management Center, Philadelphia, PA; Christopher J. Schultz and Joseph A. Bovi, Medical College of Wisconsin, Milwaukee, WI; Daniel Brat, Emory University, Atlanta, GA; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; John H. Suh, Cleveland Clinic, Cleveland, OH; Barbara Jean Fisher, London Regional Cancer Program, London, Ontario, Canada; Marcia K. Liepman, Kalamazoo CCOP-West Michigan Cancer Center, Kalamazoo, MI; Mark Augspurger, Florida Radiation Oncology Group and Baptist Regional, Jacksonville, FL; Felix Bokstein, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Matthew C. Solhjem, Columbia River CCOP, Portland, OR; and Minesh P. Mehta, University of Maryland Medical Systems, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8634DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872318PMC
May 2016

Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma.

Onco Targets Ther 2016 6;9:2027-34. Epub 2016 Apr 6.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S96175DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827881PMC
April 2016

Radiation for early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a double-edged sword?

Leuk Lymphoma 2016 Feb;57(2):249-251

a Division of Oncology , Washington University School of Medicine , St. Louis, MO , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1115045DOI Listing
February 2016

A Young Woman With Blurred Vision and Distal Paresthesias.

JAMA Neurol 2015 Dec;72(12):1519-23

Department of Neurology, Washington University in St Louis, St Louis, Missouri.

View Article

Download full-text PDF

Source
http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamaneurol.2015.2390DOI Listing
December 2015

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

N Engl J Med 2015 Dec 6;373(25):2425-37. Epub 2015 Dec 6.

From the University of Texas MD Anderson Cancer Center, Houston (J.A.B.); Azienda Ospedaliera Niguarda Cà Granda (A.T.) and Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele (P.G.), Milan, and the Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara (G.G.) - all in Italy; Wilmot Cancer Institute, University of Rochester, Rochester, NY (P.M.B.); Medical University of Lodz and Copernicus Memorial Hospital, Lodz (T.R.), the Department of Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice (S.G.), and the Department of Hematology, University Clinical Center of Medical University of Gdansk, Gdansk (A.H.) - all in Poland; Tom Baker Cancer Centre, Calgary, AB, Canada (C.O.); Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv (O.B.), and Hadassah University Hospital, Hebrew University Medical School, Jerusalem (A.P.) - both in Israel; Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds (P.H.), Kings College Hospital, London (S.D.), Royal Bournemouth Hospital, Bournemouth (H.M.), and University of Oxford, Oxford (A.S.) - all in the United Kingdom; Washington University School of Medicine, St. Louis (N.L.B.); Jiangsu Province Hospital, Nanjing, China (J.L.); North Shore Hospital, Auckland, New Zealand (D. Simpson); Stanford University School of Medicine, Stanford (S.C.), City of Hope National Medical Center, Duarte (T.S.), Pharmacyclics, Sunnyvale (D. Suri, M.C., F.C., L.S., D.F.J.), and Moores Cancer Center, University of California, San Diego, San Diego (T.J.K.) - all in California; St. Vincent's Hospital, University of Melbourne (H.Q.), and Peter MacCallum Cancer Centre and St. Vincent's Hospital (C.S.T.), Melbourne, VIC, Australia; Institute of Blood Pathology and Transfusion Medicine, National Academy of Medical Sciences of Ukraine, Lviv, Ukraine (Z.M.); Norton Cancer Institute, Louisville, KY (D.A.S.);

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1509388DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722809PMC
December 2015

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).

J Clin Oncol 2015 Nov 24;33(31):3635-40. Epub 2015 Aug 24.

John P. Leonard, Meyer Cancer Center, Weill Cornell Medical College and New York Presbyterian Hospital, New York; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Sin-Ho Jung, Jeffrey Johnson, and Brandelyn N. Pitcher, Alliance Statistics and Data Center, Duke University, Durham, NC; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Kristie A. Blum, Ohio State University Medical Center, Columbus, OH; Jeffrey K. Giguere, Greenville Community Clinical Oncology Program, Greenville, SC; and Bruce D. Cheson, Georgetown University Hospital, Washington, DC.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/08/21/JCO.2014.59
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.59.9258
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.9258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622102PMC
November 2015

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

J Clin Oncol 2015 Jul 15;33(21):2399-404. Epub 2015 Jun 15.

Paul M. Barr and Jonathan W. Friedberg, University of Rochester, Rochester; Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY; Hongli Li and Michael LeBlanc, SWOG Statistical Office, Seattle, WA; Catherine Spier, University of Arizona College of Medicine, Tucson, AZ; Daruka Mahadevan, Mansoor Ul Haq, and Bryan D. Huber, University of Tennessee Health Sciences Center, Memphis, TN; Christopher R. Flowers, Emory University, Atlanta, GA; Nina D. Wagner-Johnston and Nancy L. Bartlett, Washington University School of Medicine, St. Louis, MO; Richard I. Fisher, Temple University, Philadelphia, PA; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Sonali M. Smith, The University of Chicago, Chicago, IL; and Brad S. Kahl, University of Wisconsin, Madison, WI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.6327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500834PMC
July 2015

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

J Clin Oncol 2015 Jun 20;33(17):1936-42. Epub 2015 Apr 20.

Ranjana H. Advani, Richard T. Hoppe, and Sandra J. Horning, Stanford University, Stanford; Joseph M. Tuscano, University of California, Davis Cancer Center, Sacramento, CA; Fangxin Hong, Dana-Farber Cancer Institute, Boston, MA; Richard I. Fisher and Jonathan W. Friedberg, University of Rochester, Rochester, NY; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; K. Sue Robinson, Queen Elizabeth II Health Science Center, Halifax, Nova Scotia; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia; Douglas A. Stewart, Tim Baker Cancer Institute, Calgary, Alberta, Canada; Henry Wagner Jr, Penn State Cancer Institute, Hershey, PA; Patrick J. Stiff, Loyola University Medical Center, Maywood; Leo I. Gordon, Northwestern University, Chicago, IL; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Brad S. Kahl, University of Wisconsin, Madison, WI; Kristie A. Blum, Ohio State University, Columbus, OH; and Thomas M. Habermann, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.57
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.8138
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.8138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451176PMC
June 2015

Blinatumomab for the treatment of B-cell lymphoma.

Expert Opin Investig Drugs 2015 May 4;24(5):715-24. Epub 2015 Mar 4.

Washington University School of Medicine, Division of Oncology , St. Louis, MO , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2015.1021415DOI Listing
May 2015

Biologic agents in the management of Hodgkin lymphoma.

J Natl Compr Canc Netw 2015 May;13(5):587-96

From the Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0076DOI Listing
May 2015

Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma.

Blood 2015 May;125(21):3354-5

Division of Oncology, Washington University School of Medicine, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-02-628362DOI Listing
May 2015

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.

J Clin Oncol 2014 Oct 18;32(28):3137-43. Epub 2014 Aug 18.

Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner, Takeda Pharmaceuticals International, Cambridge, MA; Dana A. Kennedy, Seattle Genetics, Bothell; Andrei R. Shustov, University of Washington Medical Center, Seattle, WA; Andrew Davies, University of Southampton School of Medicine, Southampton; Tim Illidge, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.2456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171358PMC
October 2014

Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission.

Cancer 2014 Jul 7;120(14):2122-9. Epub 2014 Apr 7.

Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28698DOI Listing
July 2014

High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis.

Leuk Lymphoma 2014 Jun 1;55(6):1345-9. Epub 2013 Nov 1.

Division of Medical Oncology, Internal Medicine, Washington University School of Medicine , St. Louis, MO , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.840780DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100682PMC
June 2014

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

J Clin Oncol 2014 Jun 5;32(17):1797-803. Epub 2014 May 5.

Ronald Levy, Andrew J. Gentles, Chih Long Liu, Robert Tibshirani, and Ash A. Alizadeh, Stanford University Medical Center, Palo Alto; Christos E. Emmanouilides and John M. Timmerman, University of California Los Angeles Medical Center, Los Angeles; Lori A. Kunkel, Diane E. Ingolia, and Dan W. Denney Jr, Genitope, Fremont, CA; Kristen N. Ganjoo and Michael J. Robertson, Indiana University Medical Center, Indianapolis, IN; John P. Leonard, Weill Medical College of Cornell University, New York, NY; Julie M. Vose, University of Nebraska Medical Center, Omaha, NE; Ian W. Flinn and Richard F. Ambinder, Johns Hopkins University Oncology Center, Baltimore, MD; Joseph M. Connors, British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, British Columbia; Neil L. Berinstein, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario; Andrew R. Belch, Cross Cancer Institute, Edmonton, Alberta, Canada; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Craig Nichols, Oregon Health Science University, Portland, OR; Stephanie A. Gregory, Rush University Medical Center, Chicago, IL; Brian K. Link, University of Iowa Hospitals and Clinics, Iowa City, IA; David J. Inwards, Mayo Clinic, Rochester, MN; Arnold S. Freedman, Dana-Farber Cancer Institute, Boston, MA; and Jeffrey V. Matous, Rocky Mountain Cancer Centers, Denver, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.43.9273DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039868PMC
June 2014

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

Blood 2014 May 20;123(20):3095-100. Epub 2014 Mar 20.

Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-12-542142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425442PMC
May 2014

CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma.

Am J Clin Pathol 2014 Mar;141(3):381-7

Dept of Pathology and Immunology, Washington University Medical Center, 660 S. Euclid Ave, Campus Box 8118, St Louis, MO 63110; e-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1309/AJCP61TLMXLSLJYSDOI Listing
March 2014

Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.

J Clin Oncol 2014 Mar 10;32(9):912-8. Epub 2014 Feb 10.

Ranjana H. Advani, Sandra J. Horning, Richard T. Hoppe, Sarah Daadi, John Allen, and Yasodha Natkunam, Stanford University Medical Center, Stanford, CA; and Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.2069DOI Listing
March 2014

Highlights in lymphoma from the 2013 American Society of Hematology Annual Meeting and Exposition: commentary.

Authors:
Nancy L Bartlett

Clin Adv Hematol Oncol 2014 Feb;12 Suppl 6(2):18-23

Washington University School of Medicine, St Louis, MO.

View Article

Download full-text PDF

Source
February 2014

Commentary.

Authors:
Nancy L Bartlett

Clin Adv Hematol Oncol 2014 Feb;12(2 Suppl 6):18-23

Washington University School of Medicine, St Louis, Missouri.

View Article

Download full-text PDF

Source
February 2014

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.

J Clin Oncol 2013 Nov 16;31(32):4132-9. Epub 2013 Sep 16.

Andrew M. Evens, Tufts University School of Medicine, Boston; Aimee Kroll-Desrosiers, University of Massachusetts Medical School, Worcester, MA; Ranjana Advani and Stavroula Otis, Stanford University Medical Center, Stanford, CA; Oliver W. Press and Linda M. Parker, Fred Hutchinson Cancer Research Center, Seattle, WA; Izidore S. Lossos, Liat Nadav Dagan, and Jose Sandoval, University of Miami School of Medicine, Miami, FL; Julie M. Vose, University of Nebraska Medical Center, Omaha, NE; Francisco J. Hernandez-Ilizaliturri, Roswell Park Cancer Institute, Buffalo; Ramsey Abdallah and John P. Leonard, Weill Cornell Medical College, New York, NY; Barrett K. Robinson, Indiana University School of Medicine, Indianapolis, IN; Jessica L. Yarber and Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; Kristie A. Blum, The Ohio State University, Columbus, OH; Christopher R. Flowers, Emory University, Atlanta, GA; Thomas M. Habermann, Mayo Clinic, Rochester, MN; and Nancy L. Bartlett, Washington University School of Medicine, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.8220DOI Listing
November 2013

Therapy in primary mediastinal B-cell lymphoma.

N Engl J Med 2013 07;369(3):282-3

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1305983DOI Listing
July 2013

Treatment of nodular lymphocyte-predominant Hodgkin lymphoma-"do no harm".

Authors:
Nancy L Bartlett

Clin Adv Hematol Oncol 2013 Jun;11(6):385-7

Division of Oncology, Washington University School of Medicine, Siteman Cancer Center, St. Louis, Missouri.

View Article

Download full-text PDF

Source
June 2013